Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 11/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | SLC8A1 | P32418 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.33 |
| ▸ | HAMP | P81172 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774199 | 0.90 | CNR2 (0.38) | HCRTR1HCRTR2SLC8A1 | |
| SCHEMBL5772865 | 0.87 | ADORA2B (0.38) | HCRTR1HCRTR2SLC8A1ADORA2BADORA2A | |
| SCHEMBL5770048 | 0.83 | PIM1 (0.43) | ADORA2B | |
| SCHEMBL5768252 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2ADORA2BADORA2A | |
| SCHEMBL5773158 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2ADORA2BADORA2A | |
| SCHEMBL5773249 | 0.81 | HCRTR1 (0.42) | HCRTR1HCRTR2ADORA2BADORA2A | |
| SCHEMBL5873053 | 0.79 | KDM5A (0.37) | HCRTR1HCRTR2 | |
| SCHEMBL5773738 | 0.79 | ATR (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL5771644 | 0.79 | ATR (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL5873142 | 0.78 | ACVR1 (0.39) | ACVR1FGFR1FGFR2FGFR3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ACVR1 4477/4885FGFR1 3930/4885FGFR2 4280/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ACVR1 4477/4885FGFR1 3930/4885FGFR2 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.